Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa ucb

besponsa ucb

Перейти к контенту

Главное меню:

Разное
besponsa ucb
BESPONSA® Approved in the EU for Adult Patients with , Pfizer Receives Positive CHMP Opinion for BESPONSA , Inotuzumab ozogamicin - Wikipedia, 2017 half-year financial report - UCB, US regulators approve Pfizer's Besponsa in ALL - Pharmaphorum, Pfizer locks down US approval for Besponsa | BioPharma Dive, UCB Seminar: Antibody-enabled small molecule drug , UCB Seminar: Antibody-enabled small molecule drug , BUSINESS PERFORMANCE REVIEW - ucb.com.
This webcast may contain forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. . NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA ® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).. BESPONSA originates from a collaboration between Pfizer and Celltech, now UCB. Pfizer has sole responsibility for all manufacturing and clinical development activities for this molecule. Pfizer has sole responsibility for all manufacturing and clinical development activities for this molecule..
In 2017 inotuzumab ozogamicin was approved by the European Commission and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in 2017 under the trade name Besponsa (Pfizer/Wyeth).. Besponsa. P P originates from a collaboration between Pfizer Inc. and UCB. Pfizer has sole responsibility for all manufacturing and clinical development activities for this molecule. Upon commercialization UCB is entitled to receive royalties. 5 2017 half-year financial report Regulatory update and pipeline progress . Neurology • In January 2017, UCB filed a supplemental New Drug Application . Besponsa (inotuzumab ozogamicin) is the first of its kind to be indicated for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.. Besponsa (inotuzumab ozogamicin), for instance, is an antibody-drug conjugate (ADC) specifically targeting one CSA known as CD22. Novartis AG's CAR-T therapy tisagenlecleucel targets another one, CD19. Other CAR-T therapies in development, though, also target CD22.. Alastair Lawson has been closely involved with the discovery of UCB/Celltech’s therapeutic antibodies for some thirty-five years, with Mylotarg®, Besponsa®, Cimzia® and Evenity® FDA-approved, and bimekizumab, dapirolizumab pegol and rozanoloxizumab in clinical trials. Alastair led the development of UCB’s proprietary antibody variable region discovery platform, and is now applying . Alastair Lawson has been closely involved with the discovery of UCB /Celltech’s therapeutic antibodies for some thirty-five years, with Mylotarg®, Besponsa®, Cimzia® and Evenity® FDA-approved, and bimekizumab, dapirolizumab pegol and rozanoloxizumab in clinical trials. Alastair led the development of UCB’s proprietary antibody variable region discovery platform, and is now applying .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню